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Abstract
Background: Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies. Its rapid onset and resistance to
conventional therapeutics contribute to a mean survival of six months after diagnosis and make the identification of
thyroid-cancer-initiating cells increasingly important.
Methodology/Principal Findings: In prior studies of ATC cell lines, CD133
+ cells exhibited stem-cell-like features such as
high proliferation, self-renewal and colony-forming ability in vitro. Here we show that transplantation of CD133
+ cells, but
not CD133
2 cells, into immunodeficient NOD/SCID mice is sufficient to induce growth of tumors in vivo. We also describe
how the proportion of ATC cells that are CD133
+ increases dramatically over three months of culture, from 7% to more than
80% of the total. This CD133
+ cell pool can be further separated by flow cytometry into two distinct populations: CD133
+/
high and CD133
+/low. Although both subsets are capable of long-term tumorigenesis, the rapidly proliferating CD133
+/high
cells are by far the most efficient. They also express high levels of the stem cell antigen Oct4 and the receptor for thyroid
stimulating hormone, TSHR. Treating ATC cells with TSH causes a three-fold increase in the numbers of CD133
+ cells and
elicits a dose-dependent up-regulation of the expression of TSHR and Oct4 in these cells. More importantly,
immunohistochemical analysis of tissue specimens from ATC patients indicates that CD133 is highly expressed on tumor
cells but not on neighboring normal thyroid cells.
Conclusions/Significance: To our knowledge, this is the first report indicating that CD133
+ ATC cells are solely responsible
for tumor growth in immunodeficient mice. Our data also give a unique insight into the regulation of CD133 by TSH. These
highly tumorigenic CD133
+ cells and the activated TSH signaling pathway may be useful targets for future ATC therapies.
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Introduction
Thyroid cancer is the most common type of endocrine cancer [1].
Its incidence is increasing more rapidly than any other solid tumor -
about 3 percent per 100,000 people each year [2] - and it is now the
seventh most common cancer in women [1]. More than 90% of
thyroid cancers are derived from thyroid follicular cells, are well
differentiated and have a favorable prognosis. In contrast, anaplastic
thyroid cancer (ATC), an undifferentiated thyroid cancer, is
significantly more severe than other thyroid cancers and has a poor
prognosis. Ninety percent of patients with ATC die within six
months. Although ATC accounts for more than 50% of deaths
associated with thyroid cancer every year, the causes of this disease
are largely unknown. Current treatments for ATC are aggressive -
including surgery, radiation therapy and chemotherapy – but no
study has shown a convincing improvement in survival [3], perhaps
because they do not adequately target the cancer-initiating cells.
Most cancer therapies target differentiated or differentiating cells,
regardless of whether or not they are cancerous. However, if the
disease is due to cancer stem cells (CSCs) [4,5], this could be the
wrong approach. Like normal stem cells, CSCs can both self-renew
and produce differentiated progeny, including a phenotypically
diverse tumor cell population to drive tumorigenesis. Several lines of
evidence suggest that CSCs, which are highly resistant to standard
chemotherapeutic agents and radiation, sustain the disease in late
phases of malignancy. To date, CSCs have been isolated based on
their ability to express specific cell surface molecules in hematologic
malignancies and epithelial-cell-derived cancers, including acute
myeloid leukemia (CD34
+CD38
2CD123
+) [5], mammary carcino-
ma (CD44
+CD24
low) [6], brain tumors (CD133
+)[ 7 ] ,c o l o nc a n c e r
and melanoma (CD133
+) [8–11].
CD133 (prominin-1) is a five-transmembrane domain glycopro-
tein specifically expressed on populations of hematopoietic stem and
progenitor cells from fetal and adult cord blood, peripheral blood
and bone marrow [12–15]. Although its biological function remains
unknown, it also serves as a marker of stem cells in a variety of non-
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brain as well as prostatic epithelia, muscle, kidney, liver and corneal
stroma, and some cancerous tissues [15–24]. Recently, Zito et al
reported that, of four human ATC cell lines examined, two — ARO
and KAT-4 — contain subpopulations of CD133
+ cells that exhibit
stem cell-like features such as rapid proliferation, an ability to self-
renew and form colonies, and resistance to chemotherapy-induced
apoptosisinvitro [25].Asa result, thesepopulationsare believed to be
able to initiate tumor growth, although this hypothesis has not yet
been validated in animal models.
Here we evaluate the tumorigenic potentials of ATC-derived
CD133
+ populations in vivo. We used fluorescent-activated cell
sorting (FACS) to further divide the CD133
+ cells into two distinct
fractions: CD133
+/high and CD133
+/low. We then compared the
ability of CD133
+/high, CD133
+/low and CD133
2 cells to engraft
and give rise to subcutaneous tumors in NOD/SCID mice. We
used two xenotransplantation models in our study to explore the
possible existence of CSCs in ATC: limiting dilution transplan-
tation experiments to determine whether our xenograft system was
qualitative and capable of detecting single tumor-initiating cells,
and a serial xenograft model to test the cells’ self-renewal and
lineage capacities. We observed that, although both CD133
+/high
and CD133
+/low cells generate subcutaneous xenograft tumors
that display histology resembling the primary tumors, CD133
+/high
cells initiate earlier and more aggressive tumor growth. We also
found that thyroid-stimulating hormone (TSH), the main regulator
of thyroid gland function, is important for the growth of the
CD133
+ population. Unlike normal thyroid cells, ATC tissue
specimens were clearly positive for CD133. Our findings, together
with the identification of thyroid CSCs and the elucidation of the
role of TSH in CD133
+ cell growth, may lead to new diagnostic
markers and therapies to treat this devastating disease.
Results
CD133 is expressed on human ATC cell lines but not on
papillary thyroid cancer cell lines
To determine whether a CSC population exists in ATC, we
examinedCD133expression ina panelof humanthyroidcancer cell
lines. Flow cytometric analysis revealed that CD133 is expressed in
two ATC cell lines, ARO (in which 7.02% of cells are CD133
+)a n d
FRO (in which 6.32% of cells are CD133
+), but not in either of two
well-differentiated papillary thyroid cancer cell lines (NPA and TPC)
(Fig. 1A). These results suggest that CD133 expression is uniquely
associated with undifferentiated ATC. Immunofluorescent staining
confirms the expression of CD133 on the surface of CD133
+ but not
CD133
2 cells (Fig. 1B).Moreover,the two CD133 populations grow
differently in culture. In tumors, CD133
+ cells exhibit pleomorphic
giant cell nuclei and appear granular and dense; in two-dimensional
cultures they form tight round colonies. In contrast, CD133
2 cells
are devoid of most of these features. Similar to ARO cells, they grow
independently as small, round cells in culture (Fig 1B).
CD133
+ cells express high levels of the genes for Oct4
and TSHR
Quantitative real-time polymerase chain reaction (qRT-PCR)
analysis indicated that CD133
+ cells express about four times as
much Oct-4 as do CD133
2 cells (Fig. 2A; 1.0260.25 (mean6-
s.e.m.) versus 0.2760.10 (mean6s.e.m.), P,0.05). Oct4 is a
member of the POU family of transcription factors and plays a
key role in the maintenance of pluripotency and the proliferation
of embryonic stem cells. The expression of Oct4 in CD133
+ cells
indicates that, consistent with a previous report [25], this
population has stem-cell-like properties that are not shared with
CD133
2 cells. The CD133
+ population also expresses approxi-
Figure 1. A CD133
+ population of cancer cells is present in human ATC cell lines. (A) Flow cytometric analysis of CD133 expression in ARO,
FRO, NPA and TPC cell lines. Black lines represent positive staining for CD133, grey shows isotype controls. (B) Sorted CD133
+ cells form tight round
colonies in two-dimensional cell cultures, while CD133
2 cells grow independently as small round cells. Immunofluorescent images of CD133
+ cells
(upper middle panel; 636magnification) show CD133 expression as a green signal at the cell surface. In contrast, CD133
2 cells lack this signal (lower
middle panel; 206magnification).
doi:10.1371/journal.pone.0005395.g001
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2
population (Fig. 2A; 1.0560.53 (mean6s.e.m.) versus 0.0860.03
(mean6s.e.m.), P,0.01). TSHR is a G protein-coupled glycopro-
tein receptor that stimulates the growth of normal and cancerous
thyroid cells in the presence of TSH. Our discovery that CD133
+
cells express significantly higher levels of TSHR implies that TSH
also regulates the growth of CD133
+ cells.
Enhanced cell proliferation and up-regulation of Oct4
and TSHR genes in response to TSH signaling
Clinical studies have indicated that elevated TSH levels may be
a marker for the development of thyroid cancer [26–30]. In
particular, most thyroid cancer patients have above-normal TSH
levels. Because CD133
+ cells express much higher levels of TSHR
than do CD133
2 cells, we examined the effect of TSH on CD133
+
populations. ARO cells cultured with 0–1000 mU/ml recombinant
human TSH for 48 hours exhibited a dose-dependent increase in
the relative expression of both the TSHR and Oct4 genes (Fig. 2B).
The number of ARO cells expressing CD133 also increased about
three-fold in response to TSH treatment (Fig. 2B). Together, these
observations demonstrate that TSH induces the proliferation of
the CD133
+ populations in vitro.
ARO cells reconstitute human ATC tumors in vivo
To develop a reliable model of human ATC biology, we
established four ARO subcutaneous xenografts in eight-week-old
Figure 2. CD133
+ cells express high levels of Oct4 and TSHR genes. (A) qRT-PCR analysis indicates that CD133
+ cells express higher levels of
Oct-4 and TSHR than do CD133
2 cells. Results are shown as mean and s.e.m. Asterisk: P,0.05; two asterisks: P,0.01. (B) TSH upregulates the
expression of TSHR and Oct4 and increases the number of CD133
+ cells. Left panel: human recombinant TSH elicits a dose-dependent upregulation of
TSHR and Oct4 mRNA levels in unsorted ARO cells. Right panel: the number of CD133
+ cells increases three-fold in response to TSH stimulation.
doi:10.1371/journal.pone.0005395.g002
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sions of 10
6 ARO cells developed palpable tumors within a few
days and visible tumors within 21 days. These tumors are
remarkably similar to those from human patients and exhibit little
resemblance to the original thyroid follicle structure (Fig. 3A).
Importantly, we found that the tumorigenic potential of the ARO
cells varies with their passage number: cells that had been cultured
longer formed larger and more aggressive tumors when trans-
planted into NOD/SCID mice than did cells of lower passage
number (Fig. 3A). We speculate that this phenomenon is due to the
positive selection over time of the more robustly proliferating
CD133
+ cells at the expense of the CD133
2 cells. Indeed, we
found that two ARO cultures that had been passaged 50 or more
times contained a higher proportion (,50.1%) of CD133
+ cells
than did ARO cultures of lower passage numbers
(,21.9%)(Fig. 3B). Together, these results demonstrate that the
human ARO cell line contains cells with the capacity to form new
tumors in NOD/SCID mice and that CD133 expression levels are
positively correlated with tumor formation. Furthermore, the
rapid proliferation of CD133
+ cells results in the robust positive
selection of these cells over time—from the original 7.02% (Fig. 1A)
of the total population to more than 80% after three months of
continuous culture (Fig. 4). These results demonstrate that an
extended period of culture can transform CD133
2-dominant
populations into CD133
+-dominant populations.
CD133
+/high cells express higher levels of TSHR and Oct4
genes than do CD133
+/low and CD133
2 cells
The CD133
+ cell pool can be further separated by FACS into
two distinct subpopulations: CD133
+/high and CD133
+/low
(Fig. 4A). In a highly passaged culture of ARO cells, about 80%
of the cells were CD133
+/low, 16% were CD133
+/high, and 4%
were CD133
2 (Fig. 4A). We confirmed the purity of the fractions
after sorting (Fig. 4B) and conducted cell proliferation assays to
determine whether there are any differences in the proliferation
rates of these subpopulations. As expected, the CD133
+/high and
CD133
+/low subpopulations proliferate more rapidly than the
CD133
2 subpopulation in vitro (Fig. 4C). qRT-PCR analysis
further revealed that the CD133
+/high subpopulation expresses the
highest levels of Oct4 and TSHR, while CD133
2 cells express the
lowest levels of these genes (Fig. 4D). We also assessed the
expression of CXCR4, the receptor for the stromal cell-derived
factor-1 CXCL2 chemokine that is expressed in a variety of solid
tumors including ATC [31,32]. We found that the expression
levels of neither CXCR4 nor the endoderm marker Foxa2 differed
significantly among the three subpopulations (Fig. 4D).
CD133
+/high cells are highly tumorigenic in vivo
To test our hypothesis that only a small subpopulation of highly
proliferative ARO cells is responsible for tumor formation, we
transplanted groups of NOD/SCID mice with increasing numbers
of CD133
+/high, CD133
+/low and CD133
2 cells - from an amount
normally unable to initiate tumor growth (,1,000 cells) to an
amount that always initiates tumor growth (,100,000 cells). As
shown in Table 1, injection of 100,000 to 10,000 CD133
+/high cells
gave rise to visible tumors in all mice (4/4) within four weeks and 1
of 2 mice injected with 1,000 CD133
+/high cells developed a
tumor. In contrast, although injection of 100,000 CD133
+/low cells
also gave rise to new tumors (4/4), only 1 out of 4 mice developed
a tumor after an injection of 10,000 CD133
+/low cells, and no
tumors were observed when mice were injected with 1,000
CD133
+/low cells. No tumors were observed in mice injected with
any number of CD133
2 cells. Notably, subcutaneous tumors
derived from the injection of CD133
+/high ARO cells grew more
quickly in NOD/SCID mice than did tumors derived from
CD133
+/low cells: mice injected with 100,000 CD133
+/high cells
developed 250 mm
3 tumors within 16 days and 1000 mm
3 tumors
within 35 days whereas mice injected with 100,000 CD133
+/low
cells required 35 days to develop 250 mm
3 tumors and 45 days to
develop 1000 mm
3 tumors (data not shown). These observations
suggest that, although both CD133
+/high and CD133
+/low cells can
initiate tumors, CD133
+/high cells initiate tumor growth more
efficiently and grow more quickly than CD133
+/low cells.
Long-term tumorigenic potential of CD133
+/high and
CD33
+/low cells in NOD/SCID mice
Cells from primary tumors originating from the injection of
CD133
+/high and CD133
+/low cells were serially transplanted into
NOD/SCID mice to determine the long-term tumorigenic
potential of the cells. The limiting-dilution transplantation
experiments described above indicate that the size of the tumors
Figure 3. ARO cells reconstitute human ATC tumors in NOD/
SCID mice and high-passage ARO cells generate faster-
growing, larger tumors in NOD/SCID mice than do low-passage
ARO cells. (A) All mice injected with 10
6 ARO cells developed tumors
within 21 days. Hematoxylin-eosin analysis of these xenografts showed
that they are remarkably similar to tumor sections from human patients.
Note that tumors generated from high-passage ARO cells formed larger
and more aggressive tumors when subcutaneously transplanted into
NOD/SCID mice than did tumors generated from low-passage ARO cells.
(B) FACS analysis show that ARO cells of high passage number (right
panel, passage number.50) contain a greater proportion of CD133
+
cells than do ARO cells of low passage number (left panel, passage
number,10).
doi:10.1371/journal.pone.0005395.g003
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+/high and
CD133
+/low cells injected. Tumors derived from CD133
+/high and
CD133
+/low primary and secondary xenografts consistently
reproduced the primary tumors at the histological level (Fig. 5).
Although both subpopulations not only maintained their tumor-
igenic potential during in vivo passaging but also increased their
aggressiveness, as indicated by the faster growth and increasing
size of successively generated tumors, the CD133
+/high cells are
overall more aggressive. Together these results suggest not only
that CD133
+/high and CD133
+/low cells have long-term tumori-
genic potential, but also that our xenograft model system
quantitatively and qualitatively recapitulates tumorigenesis in vivo.
Figure 4. CD133
+/high subpopulations express higher levels of TSHR and OCT4 genes than do CD133
+/low and CD133
2
subpopulations. (A) The CD133
+ population can be further separated into CD133
+/high and CD33
+/low populations by FACS. (B) The purity of
each sorted fraction was confirmed by FACS analysis. (C) ARO cell proliferation assay (left panel). Cell proliferation assays indicate that CD133
+/high
and CD133
+/low cells proliferate more rapidly than CD133
2 cells at culture days four and eight (right panel). (D) qRT-PCR analysis. Results are shown
as mean and s.e.m. Asterisk, P,0.05.
doi:10.1371/journal.pone.0005395.g004
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ATC but not in normal thyroid cells
To understand the role of CD133 in human ATC, it is
necessary to verify whether the CD133 protein is expressed in
surgical samples derived from patients with pathological and
clinical diagnoses of ATC. We used immunohistochemical staining
to evaluate levels of CD133 expression in a set of archival,
routinely processed, formalin-fixed, paraffin-embedded ATC
patient tissue specimens (n=10). We detected CD133 expression
in 8 out of 10 (80%) ATC specimens. Staining intensity ranged
from strong to moderate. Representative pictures of ATC
specimens are shown in Fig. 6. Strikingly, CD133 is strongly
expressed on tumor cells, but not on neighboring normal thyroid
follicular cells (Fig. 6). Antibody specificity was demonstrated
through peptide blocking. Together these data indicate that
CD133 is overexpressed in ATC clinical samples with respect to
normal thyroid tissues.
Discussion
ATC is one of the most lethal of all human neoplasms. It is
highly resistant to conventional therapies and its mortality rate
approaches 100%. The relative rarity and rapidly fatal nature of
ATC complicate both its diagnosis and treatment. The present
study demonstrates for the first time that only a subpopulation of
ATC cells is able to form tumors in NOD/SCID mice. We
identified and isolated these cells based on the expression of a cell
surface CSC marker, CD133, in the human ATC cell line ARO.
Our data demonstrate that as few as 1,000 CD133
+/high cells and
10,000 CD133
+/low cells can form tumors in NOD/SCID mice. In
contrast, mice injected with CD133
2 cells remained tumor free
throughout the study period. These data reveal that tumorigenic
and non-tumorigenic cells co-exist within ATC, and imply that not
all tumor cells are able to initiate neoplastic growth. Rather,
anaplastic tumors are generated by a small subset of CSC cells that
can self-renew and differentiate into the entire tumor population.
Our in vivo data support a previously uncharacterized CSC model
for ATC tumorigenesis [33,34].
The current approach relies on two well-characterized human
ATC cell lines: ARO and FRO. Zito et al previously reported that
over 60% of ARO cells were CD133
+, and that FRO cells did not
express CD133 [25]. In contrast, we found that about 7% of both
ARO and FRO cells were CD133
+ (Fig. 1A). Furthermore, despite
the fact that immunofluorescent staining by us (Fig. 1B) and others
clearly show that CD133 is a cell surface protein, Zito’s group
described CD133 immunostaining as cytoplasmic and apical —
atypical for a five-transmembrane glycoprotein [25]. There are
several possible explanations for these discrepancies. First, because
the sources of cell lines are different, it is possible that they
inherited different characteristics. For example, we describe here
how, like many CSCs, CD133
+/high cells proliferate more rapidly
than CD133
2 cells (Fig. 3). Over an extended period of
continuous culturing, we observed that the proportion of
CD133
+ cells in the ARO culture increased dramatically from
7% to 80%. If Zito’s group studied early-passage FRO cells they
may have mistakenly concluded that the cells did not express
CD133. A recent report by Schweppe et al also suggests that the
purported ATC cell lines ARO and KAT-4 are actually derived
from the colon cancer cell line HT-29 and are not of thyroid
cancer origin [35]. Although it is not clear whether the cell lines
used by Zito et al were contaminated, genetic analysis and DNA
fingerprinting studies should be used to clarify the identity of these
cell lines. Finally, it will be necessary to confirm our findings in
fresh human ATC surgical tissue samples because cell lines do not
always recapitulate all aspects of primary tumors. However, the
rarity of the disease may make this difficult to achieve.
The rapid proliferation of CD133
+ cells may at least partially
explain ATC’s fatal nature. Existing diagnostic methods are based
upon several characteristics: a lack of radioactive iodine uptake, a
direct extension into soft tissues, and a rapidly enlarging neck mass
(mean size at presentation: 8 cm). Most patients are struggling
with breathing problems by the time they are diagnosed, and most
of these cancers are already stage IV—they have spread
extensively to cervical lymph nodes and distant organs such as
lung and bone, and are difficult to target and kill even with
surgery. Because it is likely that the fast-growing nature of ATC
and the subsequent high casualties are due to the highly
proliferative and tumorigenic nature of CD133
+ cells, it seems
reasonable that future therapies should be designed to target
CD133
+ populations. Drug therapies targeting these populations
are likely to differ from current chemotherapies for ATC patients
and may be more successful in treating the disease.
Our immunohistochemical studies of clinical ATC specimens
clearly showed that CD133 is expressed on tumor cells but not on
neighboring normal thyroid cells. More importantly, tumors
derived from CD133
+/high and CD133
+/low primary and second-
ary xenografts faithfully reproduced the primary tumors at the
histological level in our xenograft models (Fig. 5). Together these
results suggest that CD133
+ cells maintain their tumorigenic
potential during in vivo passaging and are indeed CSCs. CSCs self-
Table 1. Limiting-dilution transplantation analysis of human ARO cells.
Cell source Cell dose
Number of primary mice with tumors/(total
number injected)
Number of secondary mice with tumors/(total
number injected)
CD133
+/high 100,000 4/4 4/4
10,000 4/4 4/4
1,000 1/2 3/4
CD133
+/low 100,000 4/4 4/4
10,000 1/4 4/4
1,000 0/4 1/4
CD133
2 10,000 0/4
1,000 0/4
Bulk 1,000,000 4/4
doi:10.1371/journal.pone.0005395.t001
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process of asymmetrical division that generates one new stem cell
and one daughter cell capable of differentiation. They can also
divide symmetrically to form either two normal daughter cells or
two stem cells, depending on surrounding extracellular factors.
Our data that CD133
+ cells generate new tumorigenic CD133
+
cells in addition to mixed populations of non-tumorigenic cells
further support the notion that they are true CSCs.
Shmelkov etalrecently reported that CD133 may not be a reliable
marker for colon CSCs. Using transgenic mice expressing LacZ
under the CD133 promoter, they found that CD133 was broadly
expressed in normal and cancerous colonic epithelium [36].
Furthermore, they reported that although both CD133
+ and
CD133
2 metastatic colon cancer cells can initiate tumors in
NOD/SCID mice,CD133
+cellscan give risetothemoreaggressive
CD133
2 cells during the metastatic transition [36]. ATC is an
Figure 5. Long-term tumorigenic potential of CD133
+/high and CD133
+/low cells. (A) CD133
+/high and CD133
+/low subsets of ARO cells each
exhibit long-term tumorigenic potential. Subcutaneous tumors in NOD/SCID mice derived from secondary injection of CD133
+/high and CD133
+/low
cells. (B) Hematoxylin-eosin (H&E) and CD133 expression analysis of mouse xenografts generated from primary and secondary xenografts.
doi:10.1371/journal.pone.0005395.g005
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from colon cancer. For example, we found that normal thyroid cells
do not express CD133. Moreover, both CD133
+/high and CD133
+/
low subsets can initiate tumor growth in NOD/SCID mice, but
CD133
+/high cells generate more aggressive tumors than CD133
+/
low cells. It is not clear in our study which CD133 subsets play a role
in ATC metastases. Our current xenograft model depends upon the
subcutaneous transplantation of CD133 cells into NOD/SCID
mice. This location is not a normal niche of thyroid cancer cells and
may not faithfully recapitulate the environment experienced by the
cancer cells in the original tumor. Although we have shown that
tumors derived from either bulk or sorted ARO cell populations are
remarkably similar to the primary tumor, it is conceivable that the
thyroid bed may better support the growth and differentiation of
thyroid CSCs. This point is even more important when we consider
that ATC is a locally aggressive type of thyroid tumor with high rate
of distant metastases. Therefore, it is critically important to establish
an orthotopic model in which tumor cells are injected directly into
the thyroid gland [37].
We found that CD133
+ cells preferentially overexpress genes,
such as Oct4, that are normally enriched in embryonic stem cells.
Our previous RT-PCR gene expression profiles indicate that ATC
cell lines express the embryonic stem cell markers Rex1, Oct4 and
Nanog. The expression of a number of endodermal markers,
including Sox17, Foxa2 and Sox 7, is also detected (data not shown).
Although these cancer cell lines also express TSHR and the thyroid
transcription factor Pax8, other markers of terminally differentiated
thyroid cells, such as the sodium-iodide symporter and thyroglob-
ulin, are not expressed in these cell lines (Friedman and Lin,
unpublished observations). These results are in agreement with those
reported byZito etalwho found that ARO/CD133
+cellsexpressthe
thyroblast-specific transcription factor TTF-1 and Oct4, but not
thyroglobulin, thyroperoxidase or sodium-iodine symporter [25].
Together these findings indicate that ATC cells have not only begun
to proliferate uncontrollably, a property common to all cancer cells,
but also that they are losing characteristics of differentiated thyroid
cells. Our results reveal a previously unknown link between genes
associated with embryonic stem cells and thyroid cells and support
Figure 6. CD133 is highly expressed in surgical samples of human ATC but not in normal thyroid cells. (A–D) Immunohistochemical
analysis of CD133 expression in ATC specimens. Positive cells are brown. Note that normal thyroid cells do not express CD133 (arrow). The photo on
the right bottom is CD133 antibody plus peptide competition staining.
doi:10.1371/journal.pone.0005395.g006
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exhibited by many tumors. These observations suggest that the
regulatory networks controlling the function of thyroid cells may also
be active in ATCs. Our discovery that TSH can regulate the
proliferation and growth of CD133
+ cells may have important
implications. Clinically, the highest incidence of thyroid cancer
occurs in patients with abnormally elevated TSH levels. We found
that CD133
+ cells overexpress the TSHR gene. Furthermore, this
expression is positively regulated by TSH, implying an autoregula-
tory feedback mechanism (Fig. 7). It is important to further
investigate how TSH affects the proliferation of CD133
+ cells and,
by extension, that of other CSCs. The role of Oct4 activation in
cancer survival and the genes and proteins that facilitate the self-
renewal of CD133
+ also warrant investigation.
In summary, our identification of these tumorigenic ATC cells is
a critical first step in understanding how TSH signaling affects the
growth of CD133
+ cells and in developing more effective therapies
for ATC. The diagnosis of ATC currently relies on a complex
panel of pathological parameters and the use of CD133 as a novel
marker to identify ATC-cancer-initiating cells may be a more
reliable way to detect and monitor cancer progression. These
findings should stimulate additional studies to determine whether
quantitative or qualitative differences in CD133 expression in
ATC have prognostic value. Furthermore, they suggest that
CD133 may itself be a potential therapeutic target in this disease.
Materials and Methods
Human thyroid cancer cell culture
Two undifferentiated human anaplastic thyroid carcinoma cell
lines (ARO and FRO), and two poorly differentiated human
papillary thyroid carcinoma cell lines (NPA and TPC), were
obtained from Dr. James Fagin (Memorial Sloan-Kettering
Cancer Center, New York). ARO, FRO and NPA cell lines were
cultured in RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS). The TPC cell line was cultured in Dulbecco’s
modified Eagle (DMEM, Gibco-BRL) high-glucose medium
containing 10% FBS. Cultures were maintained in a humidified
chamber in a 5% CO2/air mixture at 37uC. For each cell line,
15,000 to 30,000 cells were seeded in chamber slides and cultured
until they reached confluence. Cells were harvested using standard
methods. Karyotypes were determined for all the human thyroid
cancer cell lines using GTG banding. The karyogram data were
identical to the previously published reports [38–41] and
confirmed these cell lines are of human origin.
Flow cytometry
Cells were dissociated with trypsin/EDTA for three minutes,
and then washed and labeled with CD133/1(AC133)-APC
antibody (Miltenyi Biotec) and sorted on a MoFlo Cell Sorter.
Viability dye was used to eliminate dead cells. Side and forward
scatter profiles were used to eliminate cell doublets. Cell purity was
evaluated after sorting by FACS analysis. Flow cytometric analysis
was performed on a FACS Calibur flow cytometer (BD
Biosciences). FACS data were generated using FlowJo software
(FlowJo LLC. Ashland, OR).
Subcutaneous transplantation of bulk and sorted cancer
cells into NOD/SCID mice
NOD.CB17-Prkdc
scid/J (NOD/SCID) mice were obtained from
theJacksonLaboratoryand maintainedunderspecificpathogen-free
conditions with the approval of the Institutional Animal Care and
Use Committee of Mount SinaiSchool of Medicine. Bulk and sorted
CD133
+/high, CD133
+/low and CD133
2 cells were re-suspended in
PBS/Matrigel and injected subcutaneously into NOD/SCID mice.
Mice were sacrificed after four to eight weeks and the tumors were
removed, fixed in 10% formalin and embedded in paraffin in
preparationforimmunohistochemistry.Allanimalexperimentswere
performed according to approved institutional protocols.
Alamar blue assay for cell proliferation
Bulk and sorted CD133
+/high,C D 1 3 3
+/low and CD133
2 cells
were seeded in triplicate into 96-well plates at a concentration of 10
4
cells/well in RPMI/5% FBS and placed in a humidified chamber of
5% CO2/air mixture at 37uC. For cell proliferation assays, Alamar
Blue dye (Invitrogen) was added directly into culture media to a final
concentration of 10%. After an additional hour of incubation, the
plates were read in a fluorescent plate reader. As a negative control,
Alamar blue was added to cell-free medium.
Immunohistochemistry
Immunohistochemistry was performed on 10 archival routinely
processed formalin-fixed, paraffin-embedded ATC tissue speci-
mens. Paraffin sections were de-paraffined and then rehydrated
with distilled water. The slides were subsequently incubated with
anti-human CD133/1 (Abcam Inc.) antibody and visualized with
Elite vector Stain ABC systems (Vector Laboratories) and DAB
substrate (DakoCytomation) and counterstained with hematoxylin.
qRT-PCR
Total RNA was isolated with the RNeasy kit (Qiagen) and
treated with RNase-free DNase (Qiagen). Two micrograms of total
RNA were reverse transcribed into cDNA using the Thermoscript
First Strand Synthesis System (Invitrogen). Qiagen QuantiFast
SYBR Green PCR kit was used for the qRT-PCR reaction.
Figure 7. Model depicting the role of TSH signaling in ATC
development. TSH, thyroid stimulating hormone, TSHR, the receptor
for thyroid stimulating hormone, Red circle, CD133
+/high cells, blue
circle, CD133
+/low cells, yellow circle, CD133
2 cells.
doi:10.1371/journal.pone.0005395.g007
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amplifications. The primers used in this study were as follows: TSHR
(forward), 59-CCTGAGAATTGTGGTGTGGTTCGTTAG-39;
TSHR (reverse), 59-AGTTTGTAGTGGCTGGTGAGGAGAA-
39;O c t 4(forward), 59-ATGCATTCAAACTGAGGTGCCTGC-
39;O c t 4(reverse), 59-CCACCCTTTGTGTTCCCAATTCCT-39;
Foxa2 (forward), 59-GCATTCCCAATCTTGACACGGTGA-39;
Foxa2 (reverse), 59-GCCCTTGCAGCCAGAATACACATT-39;
CXCR4 (forward), 59-AGGGAACTGAACATTCCAGAGCGT-39;
CXCR4 (reverse), 59-AAACGTTCCACGGGAATGGAGAGA-39;
GAPDH (forward), 59-TGCACCACCAACTGCTTAGC-39;
GAPDH (reverse), 59-GGCATGGACTGTGGTCATGAG-39.
Statistical analysis
Statistical analysis was performed with Prism software. Numer-
ical data are expressed as mean6s.e.m. Statistical differences are
considered significant at P,0.05.
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